Terns Pharmaceuticals, Inc.

As of September 26, 2025, Terns Pharmaceuticals, Inc. shows a bullish technical trend supported by positive MACD and Bollinger Bands, despite some caution from bearish monthly indicators, while outperforming the S&P 500 recently.

As of September 26, 2025, Terns Pharmaceuticals, Inc. shows a bullish technical trend with strong weekly momentum, despite some caution from monthly indicators, and has outperformed the S&P 500 in recent weeks and year-to-date returns.

As of August 28, 2025, Terns Pharmaceuticals shows a bullish trend with strong short-term indicators, despite mixed longer-term signals and underperformance over the past year.

As of March 27, 2023, Terns Pharmaceuticals, Inc. is considered overvalued with a valuation downgrade to "does not qualify," reflected by a negative P/E ratio of -3.7684, a significant decline in stock performance, and concerning profitability metrics, indicating poor investment appeal at its current price of $3.68.

As of May 7, 2025, Terns Pharmaceuticals, Inc. shows a mildly bearish trend overall, with daily moving averages indicating bearishness, while weekly indicators suggest mild bullishness, leading to a cautious outlook.

Terns Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net loss of $24 million and a market cap of $340.62 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -27.72%.

As of Jun 18, Terns Pharmaceuticals, Inc. has a market capitalization of 340.62 million and reported net sales of 0.00 million with a net profit of -90.40 million for the latest four quarters. Shareholder's funds are at 345.87 million and total assets at 363.93 million as of Dec 24.